Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 10/20 | 0.56 |
| ▸ | PFKFB3 | Q16875 | 9/20 | 0.49 |
| ▸ | PFKFB4 | Q16877 | 9/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952553 | 0.84 | CMA1 (0.48) | CMA1PFKFB3PFKFB4 | |
| SCHEMBL2950386 | 0.80 | CMA1 (0.52) | CMA1PFKFB3PFKFB4CA12CA1 | |
| SCHEMBL14338971 | 0.79 | NPSR1 (0.50) | CMA1PFKFB3PFKFB4 | |
| SCHEMBL2953838 | 0.77 | NPSR1 (0.60) | CMA1PFKFB3PFKFB4 | |
| SCHEMBL2950569 | 0.75 | PFKFB3 (0.42) | CMA1PFKFB3PFKFB4 | |
| SCHEMBL2950050 | 0.73 | CMA1 (0.46) | CMA1PFKFB3PFKFB4CA12CA1 | |
| SCHEMBL2951665 | 0.72 | ERN1 (0.51) | CMA1PFKFB3PFKFB4CA12CA1 | |
| SCHEMBL2945363 | 0.71 | CMA1 (0.44) | CMA1PFKFB3PFKFB4CA12CA1 | |
| SCHEMBL2948556 | 0.71 | CMA1 (0.44) | CMA1PFKFB3PFKFB4CA12CA1 | |
| SCHEMBL3876651 | 0.69 | PFKFB4 (0.72) | CMA1PFKFB3PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | CMA1 2808/4885PFKFB3 4363/4885PFKFB4 4119/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | CMA1 3144/4885PFKFB3 4313/4885PFKFB4 4102/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | CMA1 4006/4885PFKFB3 3978/4885PFKFB4 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.